Washington, DC | Nov 11-15 2017
Plan to attend Neuroscience 2017 in DC this year? SynapCell will be there along with stunning outcomes. BOOTH#2126 Save the date! The SynapCell Team
Miami, USA | June 2017
Just back from Miami, USA where I had the chance to attend The Anti Epileptic Drug and Devices Trials Conference two weeks ago. We have been very proud to see that SynapCell now belongs to the restricted veteran club of this meeting, as it’s indeed been already 8 years since we’ve started
Miami, USA | May 17-19 2017
SynapCell to unveil unprecedented advances in Epilepsy at the Antiepileptic Drug Trials Conference. Contact us to select a convenient time for you to meet Corinne, CEO and founder of SynapCell. Conference Purpose The conference focuses on issues surrounding AEDD development, ranging from
Vienna, Austria | March 29 - April 2, 2017
Dear all, We are pleased to announce that we will present our latest advances in Parkinson's Disease and Dyskenesia during the AD/PD 2017 Conference. We look forward to meeting with you there! POSTER #320 Amantadine decreases L-DOPA induced cortical gamma oscillations in the 6-OHDA rat All
Grenoble and Salt Lake City | 03/11/2016
SYNAPCELL RE-ESTABLISHES PARTNERSHIP WITH THE UNIVERSITY OF UTAH TO SCREEN NOVEL ANTI-EPILEPTIC MEDICATIONS The University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP). The partnership between SynapCell and the University of
San Diego, USA | 12 - 16 NOV 2016
Save the Date! SynapCell will attend the Neuroscience 2016 Meeting. We look forward to unveiling to you our latest advances in Translational CNS Drug Discovery Services. Make the Right Decision. Stop Guessing. Meet us in San Diego!
Madrid, Spain | 26 - 29 June 2016
SynapCell will attend the 13th EILAT Conference on New Antiepileptic Drugs and Devices! Corinne ROUCARD, CEO and co-Founder will present you how the MTLE model provides an efficient way to identify new treatment for drug-resistant forms of focal epilepsies. Make the Right Decision. Stop
Berlin, Germany | 19 - 23 June 2016
Our experts will present 2 Posters on the use of EEG Biomarkers, that are both Predictive and Translational for your Parkinson's and Essential Tremor's Drug Discovery program. We're looking forward to meeting you there! Make the Right Decision. Stop Guessing.
Grenoble | February 26 2016
We are delighted to share with you the publication of our article about the MTLE mouse: a model of focal epilepsy in CNS Neuroscience and Therapeutics. Our work is entitled "Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of Mesial Temporal
Chicago | 17 - 21 October 2015
A week is already gone since I got back from the amazing adventure that Neuroscience 2015 was, with 29,033 attendees. What a pleasure to meet so many people with whom I have been in contact from afar, bringing together a face to a name! Our booth was such a great opportunity to take time to talk
Chicago | 17 - 21 October 2015
Stop guessing; think outside the box with EEG! We can help you select the most effective lead right from the earliest phase, avoiding time-consuming and costly trials. Strong of our 10 years experience of EEG in rodent models, let us show you how easy we can make it for you! We open a wide
Chicago | 17 - 21 October 2015
Coming up in a month in Chicago, Neuroscience 2015 is the world's largest source of emerging news on brain science and health, with more than 30,000 attendees! Lectures, symposia, and thousands of posters provide new understanding of how the brain works. Leading researchers explore brain
Turin | 23 - 24 September 2015
SynapCell is involved in the funded EU Project NEURINOX. Together with the project consortium, we will be hosting a symposium on Innovative Concepts for Treating Neurodegenerative Diseases. This will be held over the 23rd and 24th September at the Molecular Biotechnology Centre in Torino (Italy),
Amsterdam | August 29 - September 1st 2015
At the end of the summer, SynapCell is going to take part of the major event in neuropsychopharmacology: the annual ECNP congress, held this year in Amsterdam. Established in 1987 at the instigation of European scientists, ECNP is committed to ensuring that advances in the understanding of brain
Park city, Utah | 17 - 20 May 2015
Two majors congresses for epilepsy drug discovery are taking place this May in the USA, and of course we will be there! First will be held the Antiepileptic Drug and Device (AED) Trials XIII Conference in Miami on May 13 to 15, followed from May 17 to 20 by the ADD symposium in Park city,
Miami | 13-15 May 2015
Two majors congresses for epilepsy drug discovery are taking place this May in the USA, and of course we will be there! First will be held the Antiepileptic Drug and Device (AED) Trials XIII Conference in Miami on May 13 to 15, followed from May 17 to 20 by the ADD symposium in Park city, Utah #
France | 2nd December 2014
Synapcell to assess the potential of UCB's candidate molecules in the field of epilepsy. The two-year agreement will take advantage of SynapCell’s MTLE (mesial temporal lobe epilepsy) mouse solutions. More than 65 million people world-wide are affected by epilepsy (WHO). Full drug development
Madrid | August 31 - September 3 2014
I am just back from Madrid (Spain) where I attended Eilat XII, the conference on anti-epileptic drugs (AEDs). I believe the conference was a success, it brought together people from biotech and pharma industries, clinicians and academics to discuss epilepsy and AEDs, whether already on the
Madrid | August 31 – September 3 2014
Relocated in Madrid, Spain, August 31 - September 3 for this forthcoming edition, the twelfth Eilat Conference on new antiepileptic drug (AEDs) will be introducing debates as a new feature. These debates are added to the previous format of in-depth progress report on new antiepileptic drugs in
Grenoble | APRIL 24TH, 2014
The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study confirms the interest in SynapCell's strategic approach, associating animal models and EEG, as a translational marker of brain's function. Moreover,
Salt Lake City | January 29th, 2014
The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy. The University of Utah has awarded a one-year subcontract to SynapCell under the Anticonvulsant Screening Program (ASP)